Xencor Inc (Xencor) is a clinical-stage biopharmaceutical company that discovers and develops engineered monoclonal antibodies and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company product pipeline includes Vudalimab (PD1 x CTLA4), Plamotamab (CD20 x CD3), XmAb819 (ENPP3 x CD3), XmAb564 (IL-2-Fc) and XmAb104 (PD1 x ICOS). Its other pipeline includes XmAb306/RO7310729, XmAb968 and XmAb662 (IL12-Fc), among others. Xencor's Vudalimab is a bispecific antibody that simultaneously targets immune checkpoint receptors PD-1 and CTLA-4 and is designed to promote tumor-selective T-cell activation. Xencor is headquartered in Monrovia, California, the US.
Headquarters
United States of America
Address
465 N. Halstead St., Suite 200, Pasadena, California, 91107
Website
xencor.com
Telephone
1 626 3055900
No of Employees
280
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
XNCR (NASD)
Revenue (2022)
$168.3M
2.3%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-128.5%
(2022 vs 2021)
Market Cap*
$1.3B
Net Profit Margin (2022)
XYZ
-123.4%
(2022 vs 2021)
* As of and is in US$
Xencor Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Products Pipeline: | XmAb |
| Vudalimab (PD1 x CTLA4) - Metastatic Castration-Resistant Prostate Cancer, Advanced Gynecologic and Genitourinary Malignancies | |
| Plamotamab (CD20 x CD3) - B-Cell Tumors | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In February, the company entered into an agreement with Atreca to develop T cell engaging bispecific antibody directed against novel solid tumor target. |
| 2023 | Contracts/Agreements | In January, the company and Caris Life Sciences announced an expansion of their collaboration to research, develop and commercialize novel XmAb bispecific and multi-specific antibodies directed against novel targets. |
| 2021 | Contracts/Agreements | In October, the company and Janssen Biotech entered into an agreement for the development and commercialization of plamotamab and XmAb CD28 bispecific antibody combinations to treat patients with B-cell malignancies. |
Competitor Comparison
| Key Parameters | Xencor Inc | Pfizer Inc | AbbVie Inc | AstraZeneca Plc | Bristol-Myers Squibb Co |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United Kingdom | United States of America |
| City | Pasadena | New York | North Chicago | Cambridge | Princeton |
| State/Province | California | New York | Illinois | England | New Jersey |
| No. of Employees | 280 | 88,000 | 50,000 | 89,900 | 34,100 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Bassil I Dahiyat | President; Director; Chief Executive Officer | Executive Board | 2005 | 52 |
| Bart Cornelissen | Chief Financial Officer; Senior Vice President | Senior Management | - | - |
| Allen Yang, Ph.D., MD | Senior Vice President; Chief Medical Officer | Senior Management | 2019 | 55 |
| John R Desjarlais | Senior Vice President - Research; Chief Scientific Officer | Senior Management | 2014 | 58 |
| Jennifer Sandoz | Vice President - Human Resource | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward